Market
Conversion price set at 2,954 won; 3,385,240 shares convertible 10 billion won in operating funds to support overseas expansion and product commercialization

Remed will raise funds for expansion into North America, Japan and Europe, among other uses, by issuing 10 billion won in convertible bonds (CBs).
Remed disclosed that its board of directors met on the 14th and approved the issuance of 10 billion won in its fourth series of privately placed, registered, unsecured, interest-bearing convertible bonds.
The convertible bonds will carry a coupon rate of 1.0% and a maturity yield of 5.0%. They will mature on Oct. 26, 2031, and both the subscription date and payment date are Oct. 26, 2026.
The conversion price is 2,954 won. Conversion would result in the issuance of 3,385,240 registered common shares, equivalent to 11.18% of the total shares outstanding.
The conversion period runs from Oct. 27, 2027, through Sept. 26, 2031.
The full 10 billion won raised will be used for operating expenses. Specifically, 6 billion won is allocated to expansion and growth in North America, Japan and Europe; 2 billion won to B2C product development and commercialization; and 2 billion won to BCI-related projects and validation of commercialization potential.
By year, the company plans to spend 1.7 billion won in 2026, 6.6 billion won in 2027 and 1.7 billion won from 2028 onward.
The bonds will be issued to LF Investment. However, the subscriber is expected to change to Medtech No. 1 New Technology Investment Association (tentative name), which LF Investment and Pointers Private Equity plan to form as joint managing general partners.
Bondholders may request early redemption every three months, beginning on the date 24 months after issuance and ending the day before maturity. The early redemption rate will increase in stages from 108.00% for the first payment to 119.75% for the 12th.
The company may exercise a call option on four occasions from October 2028 through October 2029. The amount subject to purchase may not exceed 30% of the total electronically registered principal.
Including this issuance, the total number of shares convertible from outstanding convertible bonds is 4,528,505, or 14.96% of the total shares issued.

Biobook Team
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss